Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
← catalyst calendarNCT04736173 · readout ≤ 284 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Gilead Sciences.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
169actual
Sites
44
Countries
Hong Kong, Malaysia, Mexico +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-08 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer
Interventions
- Drug: Domvanalimab — also filed as AB154
- Drug: Zimberelimab — also filed as AB122
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Pemetrexed
- Drug: Pembrolizumab
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS)
measured From randomization until death from any cause (up to 7 years)
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed